Koru Med Sys SEC Filings

KORU Medical Systems, Inc. entered into an Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc. on November 19, 2025. Effective as of January 1, 2024, the agreement replaces a prior manufacturing and supply agreement dated November 11, 2020.

Under the agreement, Command will manufacture and supply KORU’s subassemblies, needle sets and tubing products according to KORU’s specifications and purchase orders. The agreement runs through December 31, 2026 and automatically renews for one-year terms unless either party elects not to renew under its terms.

Either party may terminate the agreement for an uncured material breach within 45 days, upon the other party’s bankruptcy or insolvency, or as otherwise provided. The agreement also sets out terms for pricing and payment, rebates, purchase commitments based on KORU’s forecasts, and includes customary provisions covering delivery, inspection, warranties, quality management, business continuity, handling and transport, intellectual property, confidentiality and indemnification.

KORU Medical Systems (KRMD) reported Q3 2025 results with net revenues of $10.4 million, up 27.2% year over year. Core revenue reached $9.8 million (up 29.7%), driven by international core growth of 229.6%, while domestic core declined 5.0% due to ordering shifts and inventory reductions at a U.S. distributor.

Gross profit was $6.3 million, up 20.8%, with gross margin of 60.2% versus 63.4% a year ago, reflecting higher manufacturing costs, geographic mix, and tariff charges. Operating expenses were $7.1 million, modestly higher than last year. Net loss narrowed to $0.8 million from $1.6 million.

For the nine months, revenue was $30.2 million (up 21.9%) with a net loss of $2.2 million versus $4.5 million last year. Cash and cash equivalents were $8.5 million as of September 30, 2025, and there were no outstanding borrowings under the $5 million revolver or $5 million term facility. Management noted tariff-related charges of $0.1 million in Q3 and expects an annualized gross margin impact of less than 100 basis points.

KORU Medical Systems (KRMD) reported Q3 2025 results and updated its full‑year 2025 financial guidance via a press release furnished as Exhibit 99.1. The quarter covered the period ended September 30, 2025, and a conference call was scheduled for November 12, 2025 at 4:30 p.m. Eastern Time.

The company highlighted use of non‑GAAP measures, including adjusted EBITDA and adjusted diluted EPS, with definitions provided and reconciliations to GAAP included in the press release. Management views these metrics as helpful for comparing ongoing operations. The information under Item 2.02 is furnished, not filed, and is not subject to Section 18 liabilities.

KORU Medical Systems (KRMD) reported an insider equity transaction. On 10/16/2025, the President and CEO was issued 29,463 shares of common stock at $4.08 per share under her employment agreement as the stock portion of the 2024 annual bonus (30% stock, 70% cash).

Following the transaction, she beneficially owned 1,052,626 shares. This includes 200,000 restricted stock awards that vest based on a market capitalization schedule prior to 3/15/27, and 600,000 restricted stock awards that vest based on net sales growth targets for fiscal years ended 12/31/22 through 12/31/25.

Edward Wholihan, a director of KORU Medical Systems, Inc. (KRMD), reported a purchase of 3,916 shares of the company’s common stock on 10/02/2025 at a price of $3.83 per share. Following the transaction the reporting person beneficially owned 41,688 shares. The filing is a Form 4 statement of changes in beneficial ownership and was signed by Thomas Adams as attorney-in-fact.

KORU Medical Systems director Matin Shahriar reported a purchase of 3,916 shares of KORU Medical Systems, Inc. (KRMD) on 10/02/2025 at a reported price of $3.83 per share. Following this transaction the reporting person beneficially owns 91,520 shares. The filing was submitted on Form 4 and signed by an attorney-in-fact.

Fletcher R. John, identified as Chairman of the Board of KORU Medical Systems, Inc. (KRMD), reported a purchase of 5,874 shares of the issuer's common stock at a price of $3.83 per share on 10/02/2025. After the transaction he beneficially owns 217,720 shares. The Form 4 notes the filing is submitted under a previously granted power of attorney and clarifies it should not be taken as an admission of beneficial ownership under Section 16. No derivative transactions or other security classes are reported.

KORU Medical Systems director Robert Cascella reported an open-market purchase of 3,916 shares of KORU Medical Systems, Inc. (KRMD) on 10/02/2025 at a reported price of $3.83 per share. After the transaction he beneficially owned 88,531 shares. The Form 4 was signed by an attorney-in-fact and includes a standard remark that a power of attorney has been previously filed.

Joseph M. Manko Jr., a director and reported 10% owner, filed a Form 4 for KORU Medical Systems, Inc. (KRMD). The filing shows a transaction dated 09/30/2025 where he acquired 3,916 shares of Common Stock at a reported price of $0, and reports 5,871,335 shares beneficially owned indirectly through Horton Capital Partners Fund, LP. The Form also reports a disposition of 517,200 shares.

The Form 4 is signed by Mr. Manko with signature dates of 10/02/2025. The filing references an Exhibit 99.1 for explanations of two notes tied to the reported acquisition and indirect ownership. No additional financial metrics, option holdings, or exercise/expiry dates are disclosed in the filing text provided.